Product Description
Cyclerion is advancing CY3018, a next-generation sGC stimulator to provide therapeutic benefit to individuals living with CNS diseases associated with neuroinflammation. (Sourced from: https://ir.cyclerion.com/news-releases/news-release-details/cyclerion-announces-publication-preclinical-data-demonstrating)
Mechanisms of Action: sGC Stimulant
Novel Mechanism: No
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Cyclerion Therapeutics
Company Location: Eastern America
Company CEO: Peter M. Hecht
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Nervous System Malformations
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
01/05/2026 |
News Article |
Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression |
|
09/23/2025 |
News Article |
Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company |
|
12/17/2024 |
News Article |
Cyclerion's sGC Stimulator Portfolio Generates Revenues to Enable Company Growth |
|
07/31/2023 |
News Article |
Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets |